Christopher Raymond
Stock Analyst at Piper Sandler
(2.50)
# 2,164
Out of 4,814 analysts
134
Total ratings
48.62%
Success rate
-3.41%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $0.56 | +1,507.14% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $59.12 | +113.13% | 15 | Feb 20, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $138 → $135 | $118.61 | +13.82% | 20 | Feb 18, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $2.02 | +98.51% | 3 | Feb 11, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $7 → $8 | $4.81 | +66.32% | 7 | Jan 27, 2025 | |
| BPMC Blueprint Medicines | Maintains: Neutral | $109 → $119 | $84.69 | +40.51% | 4 | Jan 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $489.10 | +8.98% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $563.16 | +79.88% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $35.64 | +292.82% | 5 | Jan 13, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $43 → $30 | $0.92 | +3,145.35% | 1 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $40.12 | +79.46% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $220 | $173.00 | +27.17% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.13 | +1,050.44% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $5.06 | +1,383.68% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $20.35 | +273.46% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.86 | +1,062.79% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $8.93 | +269.54% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $1.25 | +460.00% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $6.38 | +558.31% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $4.34 | +406.91% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $2.06 | +94.17% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $5.43 | +360.41% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $277.29 | +3.86% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $27.66 | +48.23% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $42.50 | -34.12% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $71.73 | -44.24% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $2.56 | +3,422.50% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.74 | +5,417.24% | 2 | Mar 13, 2020 |
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $0.56
Upside: +1,507.14%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $59.12
Upside: +113.13%
Biogen
Feb 18, 2025
Reiterates: Neutral
Price Target: $138 → $135
Current: $118.61
Upside: +13.82%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $2.02
Upside: +98.51%
Ardelyx
Jan 27, 2025
Maintains: Neutral
Price Target: $7 → $8
Current: $4.81
Upside: +66.32%
Blueprint Medicines
Jan 27, 2025
Maintains: Neutral
Price Target: $109 → $119
Current: $84.69
Upside: +40.51%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $489.10
Upside: +8.98%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $563.16
Upside: +79.88%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $35.64
Upside: +292.82%
Inozyme Pharma
Jan 13, 2025
Maintains: Overweight
Price Target: $43 → $30
Current: $0.92
Upside: +3,145.35%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $40.12
Upside: +79.46%
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $173.00
Upside: +27.17%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.13
Upside: +1,050.44%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $5.06
Upside: +1,383.68%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $20.35
Upside: +273.46%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.86
Upside: +1,062.79%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $8.93
Upside: +269.54%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $1.25
Upside: +460.00%
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $6.38
Upside: +558.31%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $4.34
Upside: +406.91%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $2.06
Upside: +94.17%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $5.43
Upside: +360.41%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $277.29
Upside: +3.86%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $27.66
Upside: +48.23%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $42.50
Upside: -34.12%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $71.73
Upside: -44.24%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $2.56
Upside: +3,422.50%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.74
Upside: +5,417.24%